Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
STA-5326 is an experimental drug that has been shown to block the release of interleukin-12
from peripheral blood mononuclear cells. Given this activity on the immune system, STA-5326
mesylate is a potential treatment for various autoimmune diseases, such as Crohn's disease,
that are mediated by the inappropriate expression of Th1 cytokines.
This study is evaluating the use of STA-5326 mesylate in patients with moderate to severe,
active Crohn's disease. Study visits include a screening visit, 9 treatment period visits
over 6 months and a follow-up visit that will occur 30 days following the end of treatment.
Study drug treatment will continue for up to 6 months.